Information Provided By:
Fly News Breaks for May 19, 2015
BLUE
May 19, 2015 | 08:21 EDT
JPMorgan analyst Cory Kasimov reiterates an Overweight rating on bluebird bio after the company announced this morning regulatory plans for LentiGlobin in B-thalassemia in the U.S. and Europe. Kasimov says approval could come earlier than the firm's current 2019 estimate with bluebird seeking accelerated approval in both geographies. The analyst recommends remaining a buyer of the stock ahead of the B-thalassemia data in June. Shares of the clinical-stage biotechnology company are up $5.60 to $162 in pre-market trading.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.